Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16081051rdf:typepubmed:Citationlld:pubmed
pubmed-article:16081051lifeskim:mentionsumls-concept:C0175677lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0007765lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0521390lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0022180lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0061465lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:16081051lifeskim:mentionsumls-concept:C1519355lld:lifeskim
pubmed-article:16081051pubmed:issue2lld:pubmed
pubmed-article:16081051pubmed:dateCreated2005-9-2lld:pubmed
pubmed-article:16081051pubmed:abstractTextA brain slice model was used to test the hypothesis that preconditioning with isoflurane, a commonly used volatile anesthetic in clinical practice, reduces neuronal injury caused by overstimulation of glutamate receptors. Glutamate receptors were stimulated by various concentrations of glutamate for 20 min, N-methyl-d-aspartate (NMDA) for 15 min or alpha-amino-3-hydroxy-5-methyl-4-isoxazol propionic acid (AMPA) for 15 min. Morphology of Purkinje neurons in the cerebellar slices of adult male Sprague-Dawley rats was evaluated 5 h after the agonist stimulation. Glutamate, NMDA and AMPA induced a dose-dependent decrease in the percentage of morphologically normal Purkinje neurons. The concentration to induce the maximal neurotoxic effect was 300 microM for glutamate, 300 microM for NMDA and 30 microM for AMPA. Isoflurane preconditioning (2% isoflurane for 30 min and then a 15-min rest period before the agonist stimulation) significantly reduced the neurotoxicity induced by 300 microM glutamate, 300 microM NMDA or 30 microM AMPA. Isoflurane preconditioning-induced protection against glutamate neurotoxicity was abolished by two protein kinase C (PKC) inhibitors, calphostin C (0.5 microM) and chelerythrine (5 microM), or a nitric oxide synthase (NOS) inhibitor, l-nitro(G)-arginine methyl ester (l-NAME, 1.5 mM), but was not affected by an adenosine A1 receptor inhibitor, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 300 nM), or a Gi protein inhibitor, pertussis toxin (PTX, 200 ng/ml). Isoflurane preconditioning-induced protection against NMDA neurotoxicity was also abolished by calphostin C, chelerythrine or l-NAME. Thus, isoflurane preconditioning reduced glutamate receptor overstimulation-induced neuronal injury/death. This neuroprotection may be PKC- and NOS-dependent.lld:pubmed
pubmed-article:16081051pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:languageenglld:pubmed
pubmed-article:16081051pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:citationSubsetIMlld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16081051pubmed:statusMEDLINElld:pubmed
pubmed-article:16081051pubmed:monthAuglld:pubmed
pubmed-article:16081051pubmed:issn0006-8993lld:pubmed
pubmed-article:16081051pubmed:authorpubmed-author:VâlcuMMlld:pubmed
pubmed-article:16081051pubmed:authorpubmed-author:ZhengShuqiuSlld:pubmed
pubmed-article:16081051pubmed:issnTypePrintlld:pubmed
pubmed-article:16081051pubmed:day30lld:pubmed
pubmed-article:16081051pubmed:volume1054lld:pubmed
pubmed-article:16081051pubmed:ownerNLMlld:pubmed
pubmed-article:16081051pubmed:authorsCompleteYlld:pubmed
pubmed-article:16081051pubmed:pagination143-51lld:pubmed
pubmed-article:16081051pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:meshHeadingpubmed-meshheading:16081051...lld:pubmed
pubmed-article:16081051pubmed:year2005lld:pubmed
pubmed-article:16081051pubmed:articleTitleIsoflurane preconditioning decreases glutamate receptor overactivation-induced Purkinje neuronal injury in rat cerebellar slices.lld:pubmed
pubmed-article:16081051pubmed:affiliationDepartment of Anesthesiology, University of Virginia Health System, One Hospital Drive, P.O. Box 800710, Charlottesville, VA 22908-0710, USA.lld:pubmed
pubmed-article:16081051pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16081051pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16081051pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:16081051pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:16081051pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16081051pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16081051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16081051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16081051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16081051lld:pubmed